Rivaroxaban
Respiratory Insufficiency
Janssen Research & Development, LLCSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Respiratory Insufficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oliceridine University of Tennessee | Phase 4 | BB |
NEPENTHE Northwestern University | Phase 4 | BB |
NEPENTHE Northwestern University | Phase 4 | BB |
FENTANYL BioDelivery Sciences International | Phase 3 | BB |
HYDROMORPHON Northwestern University | Phase 4 | B |
HYDROMORPHON Northwestern University | Phase 4 | B |
Buprenorphine BioDelivery Sciences International | Phase 1 | CC |
Oxycodone BioDelivery Sciences International | Phase 1 | CC |
Same molecule, other indications
Rivaroxaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →